Letybo (Botulinum Toxin Type A)

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction by cleaving the SNAP‑25 protein. This prevents nerve signals from triggering muscle contraction, leading to a localized, reversible reduction in muscle activity that alleviates symptoms associated with overactive muscles.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, muscle groups involved, and patient characteristics. The healthcare provider determines the appropriate units and injection sites to achieve the desired therapeutic effect while minimizing risk.

Safety data for Letybo in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified prescriber after careful consideration.

To request Letybo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed), and import documentation.

Letybo contains botulinum toxin type A, the same active class found in other branded neurotoxins. Differences may lie in formulation, potency units, and approved indications. Clinical choice often depends on physician experience, regulatory approvals, and specific patient needs rather than a single superiority claim.

Letybo must be stored refrigerated between 2 °C and 8 °C. It should be kept in its original packaging, protected from light, and never frozen or shaken. Proper cold‑chain management ensures product stability and efficacy up to the expiration date.

Letybo is delivered by a trained healthcare professional via intramuscular injection. The prescriber selects the appropriate injection sites and dosage units based on the targeted muscle groups and therapeutic goal, using aseptic technique to minimize infection risk.

Serious risks include the spread of toxin effect leading to dysphagia, respiratory compromise, generalized muscle weakness, and severe allergic reactions such as anaphylaxis. Patients should be monitored closely after injection, and any signs of systemic involvement should prompt immediate medical attention.

Letybo is contraindicated in individuals with known hypersensitivity to botulinum toxin type A or any of its excipients. Patients with certain neuromuscular disorders, such as myasthenia gravis or Lambert‑Eaton syndrome, should avoid use or be treated with extreme caution under specialist supervision.